MiMedx will release Q3 2025 financial results on October 29, followed by a management conference call.
Quiver AI Summary
MiMedx Group, Inc. announced that it will release its third-quarter financial results for 2025 on October 29, following market close. The company's management will hold a webcast and conference call at 4:30 p.m. Eastern Time to discuss these results, with access available to U.S. and international investors via provided phone numbers. A replay of the webcast will be accessible for 30 days on the company’s website. MiMedx is recognized for its innovation in healing solutions, focusing on chronic and difficult-to-heal wounds in the healthcare sector.
Potential Positives
- Announcement of a scheduled earnings report indicates transparency and communication with investors.
- The senior management's participation in a webcast and conference call highlights a commitment to engaging with stakeholders and providing insight into the company's performance.
- MiMedx's positioning as a pioneer in healing solutions underscores its innovative approach and leadership in the healthcare industry.
Potential Negatives
- Failure to provide specific financial guidance or forecasts for the upcoming quarter may raise concerns among investors regarding the company's future performance.
- The lack of detailed information about recent operational challenges or market conditions may leave stakeholders uncertain about the company's current position and strategy.
FAQ
When will MiMedx report its Q3 financial results?
MiMedx will report its operating and financial results for Q3 on October 29, 2025, after market close.
How can I access the MiMedx conference call?
U.S. investors can call 877-407-6184, and international investors can call 201-389-0877 to access the conference call.
What time does the MiMedx conference call start?
The MiMedx conference call will begin at 4:30 p.m. Eastern Time on October 29, 2025.
Will there be a replay of the MiMedx webcast?
Yes, a replay of the webcast will be available for approximately 30 days on MiMedx's website after the event concludes.
What does MiMedx focus on in healthcare?
MiMedx focuses on providing solutions for wound care, burns, and surgical applications, aiding in the healing of chronic wounds.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MDXG Insider Trading Activity
$MDXG insiders have traded $MDXG stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MDXG stock by insiders over the last 6 months:
- JOSEPH H CAPPER (Chief Executive Officer) purchased 200,000 shares for an estimated $1,268,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MDXG Hedge Fund Activity
We have seen 100 institutional investors add shares of $MDXG stock to their portfolio, and 90 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST LIGHT ASSET MANAGEMENT, LLC removed 1,525,580 shares (-44.2%) from their portfolio in Q2 2025, for an estimated $9,321,293
- BLACKROCK, INC. added 1,346,741 shares (+13.2%) to their portfolio in Q2 2025, for an estimated $8,228,587
- TRIGRAN INVESTMENTS, INC. added 790,901 shares (+10.4%) to their portfolio in Q2 2025, for an estimated $4,832,405
- ROYCE & ASSOCIATES LP removed 577,703 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,529,765
- AMERIPRISE FINANCIAL INC added 548,767 shares (+5332.5%) to their portfolio in Q2 2025, for an estimated $3,352,966
- MILLENNIUM MANAGEMENT LLC added 442,379 shares (+35.9%) to their portfolio in Q2 2025, for an estimated $2,702,935
- NORGES BANK removed 417,900 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,553,369
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MDXG Analyst Ratings
Wall Street analysts have issued reports on $MDXG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 07/31/2025
To track analyst ratings and price targets for $MDXG, check out Quiver Quantitative's $MDXG forecast page.
Full Release
MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2025 after the market close on Wednesday, October 29, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.
The conference call can be accessed using the following information:
Webcast:
Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13755619
A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit
www.mimedx.com
.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
[email protected]
